-
Mashup Score: 2High-Risk Patients With MM Show Favorable Outcomes After HSCT | Blood Cancers Today - 14 hour(s) ago
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Dr. Shaughnessy Outlines FELIX Trial of Obe-Cel in Relapsed, Refractory B-ALL | Blood Cancers Today - 18 hour(s) ago
Of the 127 patients who received obe-cel infusion, 74% achieved CR/CRi and 95% had MRD negativity.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
🙌 ICYMI: Paul Shaughnessy, MD (@PaulS1594), of @MethodistMDs_SA, discusses the FELIX study of obe-cel in relapsed or refractory B-ALL. 📺 Watch here: https://t.co/Ii9fuBk9jH https://t.co/n7bf9Wjo0M
-
-
Mashup Score: 3AUGMENT-101: Revumenib Shows ‘Clinically Meaningful Results’ in KMT2Ar AML, ALL | Blood Cancers Today - 22 hour(s) ago
Revumenib monotherapy achieved high overall response rates and measurable residual disease (MRD) negativity rates.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
✅ In the AUGMENT-101 trial led by Ibrahim Aldoss, MD, of @cityofhope, revumenib monotherapy achieved high ORR and MRD negativity rates in patients with KMT2Ar acute leukemias. 📰 Read more: https://t.co/FNROGE8M20 https://t.co/hQkfyAmpSU
-
-
Mashup Score: 2Cilta-Cel Shows ‘Promising Efficacy, Safety’ in Newly Diagnosed MM | Blood Cancers Today - 2 day(s) ago
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM who have had suboptimal response to frontline HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
✅ Cilta-cel + lenalidomide maintenance provides deep and durable responses in patients with multiple #myeloma who have had suboptimal response to frontline #HSCT. 📰 Read more from a study led by Bertrand Arnulf, MD, PhD, of @HopSaintLouis. ➡️ https://t.co/AZgv0TUABa https://t.co/Kn6LJPwT0w
-
-
Mashup Score: 1
Adding isatuximab to standard-of-care regimens improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
❓ What is the impact of adding isatuximab to SOC regimens for patients with transplant-eligible, newly diagnosed multiple #myeloma? #MMsm 💡 Learn more from a study presented at #SOHO2024: ➡️ https://t.co/slnCUIX19Q https://t.co/oD9oCQEegZ
-
-
Mashup Score: 4
A roundtable discussion focused on myelodysplastic syndromes.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
ICYMI: Check out our #MDS roundtable discussions from #ASH23! Featuring Drs. Guillermo Garcia-Manero, Jamie Koprivnikar, @george_yaghmour, @drsangeetmd, Hana Safah, Jamile Shammo, @andrewbrunner, and @tiffytanaka. 📺 https://t.co/VtpPy0qxf2 https://t.co/qpdpG1ti66
-
-
Mashup Score: 3Panel Describes Dosing Considerations for Luspatercept in Lower-Risk MDS | Blood Cancers Today - 3 day(s) ago
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
😍 New #MDS roundtable segment out now! 🎙️ Drs. Guillermo Garcia-Manero (@MDAndersonNews), Jamie Koprivnikar (@HMHNewJersey), Solly Chedid (@mySingingRiver), & @tomleblancMD (@DukeCancer) share their thoughts on dosing considerations for luspatercept. ➡️ https://t.co/9q32DWrvFz https://t.co/9V6l95CwpQ
-
-
Mashup Score: 5
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🚨 Out now!! 🚨 @szusmani, of @MSKCancerCenter, hops on "The HemOnc Pulse" podcast to discuss notable presentations on multiple #myeloma from #SOHO2024. 🎧 Listen here! https://t.co/bnvQF1Lyo7 https://t.co/SlNHlSuGWU
-
-
Mashup Score: 1
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
☑️ An #MDS roundtable panel with Drs. Guillermo Garcia-Manero, Jamie Koprivnikar, Solly Chedid, and @tomleblancMD outlined four COMMANDS trial abstracts on luspatercept versus epoetin alfa in lower-risk #MDS. 📺 Watch here! https://t.co/uOVDbDU2FC https://t.co/6KurQBlkWF
-
-
Mashup Score: 1
The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🎉 Obe-cel has received FDA approval for relapsed of refractory B-ALL. 📰 Read what Elias Jabbour, MD, of @MDAndersonNews, has to say about this "milestone approval." ➡️ https://t.co/BBc3gaxceQ https://t.co/em0jHFT9cv
-
A study presented at #SOHO2024 demonstrated favorable outcomes among high-risk patients with newly diagnosed multiple #myeloma who received autologous #HSCT consolidation. 📰 https://t.co/HLwEpB5Ida https://t.co/wMTWdNAfBD